Streetbeat News

TCBP

TC Biopharm (Holdings) Plc

https://www.tcbiopharm.com

Industry

Biotechnology

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Open

0.78

Mkt cap

188K

Volume

27M

High

0.96

P/E Ratio

N/A

52-wk high

138.00

Low

0.56

Div yield

N/A

52-wk low

0.56

TC BioPharm has closed a public offering of 2 million American Depositary Shares (ADSs) and Series G warrants at $1 per ADS. The warrants are priced at £0.78 per ADS and will expire in one year.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 3:31 pm

TC BioPharm (NASDAQ:TCBP) shares dropped 44% to $2.00 after announcing a 2 million unit offering at $1 per unit. The funds will support a clinical trial for Acute Myeloid Leukemia and other expenses. The stock has decreased 96.36% over the past year and 59.44% over the past month, with an RSI of 20.56 indicating oversold conditions.

Portfolio Pulse from Henry Khederian

August 14, 2024 | 1:21 pm

TC BioPharm shares are trading lower after the company announced the pricing of an offering of 2 million units at $1 per unit.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 11:56 am

Serve Robotics Inc. (NASDAQ:SERV) shares rose 14% in pre-market trading after reporting better-than-expected second-quarter sales. Other notable pre-market movers include Digital Ally, Inc. (NASDAQ:DGLY) up 80.7% after a patent grant, and Ouster, Inc. (NYSE:OUST) down 16.9% after weak sales results and guidance.

Portfolio Pulse from Avi Kapoor

August 14, 2024 | 9:35 am

TC BioPharm shares are trading lower after the company announced the pricing of a 2 million unit offering at $1 per unit.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:57 pm

TC BioPharm has announced the pricing of a 2 million unit offering at $1 per unit in a registered direct offering.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:33 pm

Trading halt status for TCBP was updated at 8:55:00 AM ET. The halt was due to pending news and the resumption times were provided.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 12:55 pm

Trading for TCBP was halted at 7:50:00 p.m. ET due to pending news.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 11:50 pm

TC BioPharm shares are trading lower after the company announced a change in its ADS ratio from 1 ADS representing 20 ordinary shares to 1 ADS representing 200 ordinary shares.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 6:53 pm

TC BioPharm has announced a change in the ratio of its American Depositary Shares (ADS) from 1 ADS representing 20 ordinary shares to 1 ADS representing 200 ordinary shares, effective August 5, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 12:05 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.